Literature DB >> 8781430

Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children.

C B Bäumler1, T Böhler, I Herr, A Benner, P H Krammer, K M Debatin.   

Abstract

Increased apoptosis of CD4+ T cells is considered to be involved in CD4+ T-cell depletion in human immunodeficiency virus type-1 (HIV-1)-infected individuals progressing toward acquired immunodeficiency syndrome (AIDS). We have recently shown that CD95 (APO-1/Fas) expression is strongly increased in T cells of HIV-1-infected children. In this report we provide further evidence for a deregulated CD95 system in AIDS. CD95 expression in HIV-1+ children is not restricted to previously activated CD45RO+ T cells but is also increased on freshly isolated naive CD45RA+ T cells. In addition, specific CD95-mediated apoptosis is enhanced in both CD4+ and CD8+ T cells. Furthermore, levels of CD95 ligand mRNA are profoundly increased. Specific T-cell receptor/CD3-triggered apoptosis in HIV-1+ children is more enhanced in CD8+ than in CD4+ T cells. Accelerated activation induced cell death of T cells could partially be inhibited by blocking anti-CD95 antibody fragments. These data suggest an involvement of the CD95 receptor/ligand system in T-cell depletion and apoptosis in AIDS and may open new avenues of rational intervention strategies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8781430

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

Authors:  H Walczak; M A Degli-Esposti; R S Johnson; P J Smolak; J Y Waugh; N Boiani; M S Timour; M J Gerhart; K A Schooley; C A Smith; R G Goodwin; C T Rauch
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

Review 2.  Role of the Fas/Fas ligand apoptotic pathway in human immunodeficiency virus type 1 disease.

Authors:  D Kaplan; S Sieg
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

Review 3.  Receptors and ligands that mediate activation-induced death of T cells.

Authors:  M R Alderson; D H Lynch
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.

Authors:  Alberto Cagigi; Nicola Cotugno; Carlo Giaquinto; Luciana Nicolosi; Stefania Bernardi; Paolo Rossi; Iyadh Douagi; Paolo Palma
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

Review 5.  Using death to one's advantage: HIV modulation of apoptosis.

Authors:  T M Ross
Journal:  Leukemia       Date:  2001-03       Impact factor: 11.528

6.  CD4+ T cells in HIV infection show increased levels of expression of a receptor for vasoactive intestinal peptide, VPAC2.

Authors:  Hayley Ipp; Bongani B Nkambule; Timothy D Reid; Dalene de Swardt; Linda-Gail Bekker; Richard H Glashoff
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

7.  Vitamin E inhibits CD95 ligand expression and protects T cells from activation-induced cell death.

Authors:  Min Li-Weber; Markus A Weigand; Marco Giaisi; Dorothee Süss; Monika K Treiber; Sven Baumann; Elena Ritsou; Raoul Breitkreutz; Peter H Krammer
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

8.  Kinetics of T lymphocyte apoptosis and the cellular immune response in SIVmac239-infected rhesus macaques.

Authors:  Mareike Meythaler; Sarah Pryputniewicz; Amitinder Kaur
Journal:  J Med Primatol       Date:  2008-12       Impact factor: 0.667

9.  Akt and SHIP modulate Francisella escape from the phagosome and induction of the Fas-mediated death pathway.

Authors:  Murugesan V S Rajaram; Jonathan P Butchar; Kishore V L Parsa; Thomas J Cremer; Amal Amer; Larry S Schlesinger; Susheela Tridandapani
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

10.  CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling.

Authors:  Gudrun Strauss; Jonathan A Lindquist; Nathalie Arhel; Edward Felder; Sabine Karl; Tobias L Haas; Simone Fulda; Henning Walczak; Frank Kirchhoff; Klaus-Michael Debatin
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.